patients malignant melanoma treated boron neutron capture therapy bnct using bpa estimation absorbed dose optimization treatment dose based pharmacokinetics bpa melanoma patients described doses measured using small tlds mg2sio4 tb thermal neutron fluence measured using gold foil wire total absorbed dose tissue bnct obtained summing primary capture doses high let radiation doses 10bn alpha7li 14nnp14c reactions key point dose optimization skin surrounding tumour irradiated NUMBER maximum tolerable dose skin regardless tumor neutron fluence optimized follows NUMBER 10b concentration blood measured min start neutron irradiation NUMBER skin estimated multiplying blood 10b value factor NUMBER NUMBER neutron fluence calculated absorbed doses skin ranged NUMBER NUMBER patients NUMBER NUMBER patients exhibited tolerable skin damage patients showed skin damage exceeded tolerance level cured months bnct remaining developed severe skin damage requiring skin grafts absorbed doses tumor ranged NUMBER NUMBER percentage complete response NUMBER bnct used treatment malignant melanoma based pharmacokinetics bpa radiobiological considerations promising clinical results obtained problems issues remain solved 10b p boronophenylalanine gamma rays gamma ray gy eq 10b concentration NUMBER NUMBER 10b concentration gy eq gy eq NUMBER NUMBER